葵花药业（002737）公告，控股孙公司葵花药业集团湖北武当有限公司近日收到国家药品监督管理局下 发的双醋瑞因胶囊申请注册上市许可的《受理通知书》。该药品为胶囊剂，注册分类为化学药品4类， 拟定适应症为用于髋、膝关节的骨关节炎治疗。公司将积极推进该产品的上市许可工作并持续关注审批 情况。 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-028 为进一步加强与投资者的互动交流，葵花药业集团股份有限公司（以下简称 "公司"或"本公司"）将参加由黑龙江省上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年黑龙江辖区上市公司投资者集体接待日活动"，现将 相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景 路演APP,参与本次互动交流。活动时间为2025年5月14日（周三）14:00-16:30。 届时公司高管将在线就公司 2024 年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交 流，欢迎广大投资者踊跃参与！ 特此公告。 葵花药业集团股份有限公司 董事会 2025 年 5 月 7 日 1 葵花药业集团股份有限公司 关于参加黑龙江辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 ...

Core Viewpoint - The recent annual report of Kew Flower Pharmaceutical (葵花药业) for 2024 indicates a revenue of 3.377 billion yuan and a net profit of 492 million yuan, reflecting the company's resilience amid industry challenges such as medical insurance cost control and large-scale drug procurement [1][2]. Financial Performance - In Q1 2024, Kew Flower achieved total revenue of 663 million yuan and a net profit attributable to shareholders of 57.11 million yuan [1]. - The company's contract liabilities increased significantly from less than 100 million yuan in Q3 to 284 million yuan in Q4, indicating potential future revenue and profit growth [2]. - Despite a year-on-year decline in Q1 2025 revenue, there was a notable 62% quarter-on-quarter growth, suggesting a positive trend in business recovery [2]. Dividend Policy - Kew Flower plans to distribute a cash dividend of 5 yuan per 10 shares, totaling approximately 292 million yuan, which represents 59.34% of the net profit attributable to shareholders [3]. - The company has a history of high dividend payouts, having distributed a total of 4.045 billion yuan since its listing, reflecting strong profit quality and management confidence in sustainable growth [3]. Brand Strategy - Kew Flower operates under two main brands: "Kew Flower" for adult medications and "Little Kew Flower" for children's medications, with the latter covering over 60 types of pediatric drugs and maintaining a leading market position [4][5]. - The "Little Kew Flower" brand has achieved a market share of 73% in its category, showcasing its competitive strength [4]. Marketing and Distribution - The company is enhancing its marketing channels and operational efficiency through digital transformation, including the establishment of self-operated B2B and B2C platforms [6]. - Kew Flower's sales expenses decreased by 68.46% to 431 million yuan in 2024, demonstrating significant cost reduction efforts [6]. - Collaborations with local pharmacies have resulted in substantial sales growth, with O2O channels experiencing increases of 35.4% and 38.8% [7]. Future Outlook - Kew Flower's strategic focus on brand empowerment and flow-driven models is expected to provide sustainable growth momentum, even in a challenging industry environment [7]. - The company aims to leverage its strong product portfolio to stabilize performance and deliver long-term returns to investors [7].

QYResearch的观点和数据因被众多国内外知名企业、证券公司及媒体频繁引用与转载，而享有高度的 品牌知名度。其权威认证确保了所提供的行业分析及定制报告的可信度与专业度，是业界信赖的优选。 0 1 恒州博智的LED照明报告被深圳民爆光电公司中的年报引用 民爆光电（301362）2024年度管理层讨论与分析 据恒州博智发布的《2023年中国LED照明行业全景图谱》显示，2023年，全球LED防爆照明市场销售额达到 了49亿元，并预测在2028年将达到79亿元，期间的复合年增长率（CAGR）约为7.8%。这一增长可归因于 LED防爆灯在石油和采矿、军事基地、机场以及其他商业和工业领域的广泛应用，这些领域对于安全照明有着 极高的要求。 来源：证券之星 更多：https://stock.stockstar.com/RB2025040100020605.shtml 最新报告推荐：2025年全球及中国极端温度LED照明企业出海开展业务规划及策略研究报告 0 2 深圳思创策划咨询有限公司引用了恒州博智出版的外墙翻新服务市场分析报告 深圳建筑外立面改造项目可行性研究报告——市场分析 根据 QYR（恒州博智）的统计及预测，2 ...

Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 17.28 CNY, compared to the current stock price of 15.63 CNY as of April 29, 2025 [5]. Core Views - The company reported a significant decline in revenue and net profit for 2024, with revenue at 3.377 billion CNY, down 40.76% year-on-year, and net profit at 492 million CNY, down 56.03% year-on-year. The first quarter of 2025 also showed a decline in revenue to 663 million CNY, down 56.30% year-on-year, and net profit at 57 million CNY, down 77.62% year-on-year [1][2]. - The company is undergoing a strategic transformation as part of its "Six Five Plan," focusing on optimizing its business model, channels, and strategies to enhance long-term competitiveness. There are signs of improvement in Q1 2025 performance compared to the previous quarter [1][2]. - The company is committed to its unique research and development path, focusing on pediatric, adult digestive, and gynecological treatments, with nearly 40 drug candidates in development as of the end of 2024 [3]. Financial Performance Summary - In 2024, the company's gross margin was 44.89%, down 11.40 percentage points year-on-year, while the net margin was 14.89%, down 5.55 percentage points year-on-year. The decline in net margin was less severe than that of gross margin due to effective cost control [2]. - For Q1 2025, the gross margin improved to 37.29%, up 45.49 percentage points quarter-on-quarter, and the net margin improved to 8.87%, up 33.93 percentage points quarter-on-quarter [2]. - The company expects revenue growth rates of 4.6%, 15.2%, and 19.0% for 2025, 2026, and 2027, respectively, with net profit growth rates of 2.5%, 31.6%, and 34.1% for the same years [8].

Core Viewpoint - Kewflower Pharmaceutical is facing significant challenges in revenue growth, with a reported revenue of 3.377 billion yuan in 2024, a substantial decline of 40.76% year-on-year, marking the lowest performance in nearly eight years [1][2] Revenue Performance - The company's revenue has fluctuated from 3.855 billion yuan in 2017 to a peak of 5.7 billion yuan in 2023, but the 2024 revenue is lower than the 3.462 billion yuan recorded in 2020 [1] - The pharmaceutical manufacturing segment saw a revenue drop of 40.87%, with traditional Chinese medicine and chemical drugs declining by 40.55% and 47.59% respectively [3] Profitability and Cash Flow - The net profit attributable to shareholders plummeted by 56.03% to 492 million yuan in 2024, reverting to levels seen seven years ago [3] - Operating cash flow for the first three quarters of 2024 was -399 million yuan, a decline of 203.01%, with a net operating cash flow of -307 million yuan for the year, down 134.56% from the previous year [4] Cost Management - In response to performance pressures, Kewflower Pharmaceutical significantly reduced sales expenses from 1.367 billion yuan to 431 million yuan, a decrease of 68.46% [3] - Despite cost-cutting measures, the gross margin continued to decline, with traditional Chinese medicine and chemical drugs' gross margins dropping by 9.75 and 8.69 percentage points respectively [3] R&D Investment - The company's R&D investment as a percentage of revenue increased from 1.86% to 3.68% in 2024, although it remains below the industry average [4] - Kewflower has around 40 drug candidates in development, focusing on pediatrics, digestion, and gynecology, while also advancing traditional Chinese medicine and health products [4] Market Strategy - Kewflower is shifting from a category-based strategy to a focus on major products, aiming to optimize its marketing and distribution channels [5] - The company has established an online platform to enhance its market reach, although the effectiveness of these strategies remains uncertain [5] Competitive Landscape - Key products like liver protection tablets and pediatric cough syrup are included in the procurement list for centralized purchasing in Anhui province, which may impact Kewflower's market position [6][7] - The company has not made it to the final procurement list, raising concerns about its competitive edge in the market [7] Pricing Pressure - The national healthcare authority is emphasizing drug price governance, which could compress profit margins in both hospital and outpatient markets [8] - A price comparison system has been implemented in various provinces, leading to significant price reductions in retail pharmacies, further squeezing profit margins [8] Channel Dependency - Kewflower's revenue heavily relies on OTC channels, which accounted for 83.23% of total revenue, with the top five customers contributing 60.41% of sales [8] - This over-reliance on traditional channels and a limited customer base poses risks during industry transitions [8]

作为OTC（非处方药）龙头企业，葵花药业选择主动应对行业变局，以短痛换长生。公司在保持研发投入强度、加快新品研发上市的同时，主动优化营销模 式、梳理下游渠道库存，推动渠道扁平化与业务数字化，缩短渠道环节，提升决策效率。 面临阶段性经营压力，也难掩葵花药业发展的坚定决心，公司仍决定以总股本5.84亿股为基数，向全体股东每10股派发现金红利5元（含税），占公司去年 净利润的近六成。 作为一家以生产中成药为主导，以"化学药、生物药"和"健康养生品"为两翼，集药品、健康养生品研发、制造与营销为一体的大型品牌医药集团企业，葵花 药业在2024年面临的挑战，可以按产品板块拆分。 其中，中成药作为公司的核心支柱，去年收入为24.64亿元，占公司总营收的72.96%；化学药和营养保健品分别实现营业收入7.13亿元和1.86亿元，占比分别 为21.10%和5.50%。 从表面来看，公司业绩的变化源于呼吸类产品在上一年度需求爆发式增长后，由于高基数效应，整体销量呈现下行回归趋势。同时，前期原材料价格高位运 行，成本压力增大，导致毛利率有所下降。 但更深层的原因，是市场环境变化。去年，公司发布半年报时曾指出，随着市场突发性事件引起 ...

证券代码：002737 证券简称：葵花药业 公告编号：2025-027 葵花药业集团股份有限公司 关于使用闲置自有资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 经葵花药业集团股份有限公司（以下简称"公司"）第四届董事会第二十九 次会议、第四届监事会第二十二次会议、公司 2023 年年度股东大会审议通过， 公司决定使用额度不超过 200,000 万元的闲置自有资金进行现金管理，存续期为 自股东大会审议通过之日起 12 个月内，在已审议的额度、期限内，资金可循环 滚动使用。 授权董事长在上述期限和额度内，行使本次现金管理的决策权并签署相关法 律文件，由公司财务部门负责具体实施。 有关上述具体内容详见《中国证券报》、《证券时报》、巨潮资讯网 （http:www.cninfo.com.cn）公司公告。 一、本次进行现金管理的实施进展情况 根据上述决议，公司于近日使用闲置自有资金 110,000 万元购买了部分理财 产品，具体情况如下： | 序 | | | | 金额 | | | 预期年化收 | 资金 | | --- | --- | --- ...

Core Viewpoint - The annual report of Kew Flower Pharmaceutical (葵花药业) for 2024 shows a stable performance with revenue of 3.377 billion yuan and a net profit of 492 million yuan, indicating a clear path for transformation in the traditional pharmaceutical industry amidst the restructuring of the Chinese medicine sector [1][11]. Group 1: Financial Performance - Kew Flower Pharmaceutical achieved an operating income of 3.377 billion yuan and a net profit attributable to shareholders of 492 million yuan in 2024 [1]. - The profit distribution plan approved by the board proposes a cash dividend of 5 yuan per 10 shares, based on a total share capital of 584 million shares as of December 31, 2024 [1]. Group 2: Industry Trends - The Chinese medicine industry is accelerating its transformation towards high-quality development, driven by policy changes such as the establishment of a standard management system for traditional Chinese medicine [3][11]. - The market demand is evolving, with increased consumer health awareness leading to a surge in chronic disease management and health maintenance needs, particularly in respiratory, cardiovascular, and wellness sectors [3][11]. Group 3: Company Strategy - Kew Flower Pharmaceutical is focusing on both internal growth through product innovation and external expansion, responding to the changing industry landscape [4]. - The company has a robust product portfolio with over 1,000 drug approval numbers, including more than 500 in the national medical insurance directory and nearly 300 in the essential drug list [5]. - Continuous product development is underway, including new formulations that cater to children's preferences and medication habits [6]. Group 4: Research and Development - The company is actively engaged in R&D with nearly 40 drug projects in development and collaborations with academic institutions to enhance innovation [7]. - A partnership with Peking University Medical School aims to establish a joint laboratory for innovative drug development, leveraging academic resources for mutual benefit [7]. Group 5: Digital Transformation - Kew Flower Pharmaceutical has completed a comprehensive digital transformation, setting a benchmark in OTC marketing and exploring new business models in digital marketing and e-commerce [8]. - Initiatives like the "Four Dragons Control Water" digital marketing project have successfully positioned certain products as market leaders, showcasing the company's ability to reach consumers effectively [8]. Group 6: Market Positioning - The company employs a "dual brand + full category" strategy, focusing on both pediatric and adult medications to create competitive barriers [9]. - Kew Flower Pharmaceutical is a leader in the pediatric medication sector, with over 60 listed products and several achieving significant sales milestones [9]. - In the adult medication market, the company targets chronic disease management, particularly in the areas of liver health and cardiovascular care, to capture new growth opportunities [10]. Group 7: Brand Value - Kew Flower Pharmaceutical has established strong brand equity with its two core brands, "Kew Flower" and "Little Kew Flower," valued at 18.432 billion yuan and 14.484 billion yuan respectively [10]. - The company's extensive product range and established brand trust contribute to its competitive advantage in a volatile market [10]. Group 8: Market Outlook - The overall market for traditional Chinese medicine is projected to reach approximately 1 trillion yuan by 2025, with significant growth potential in the Chinese patent medicine segment [11]. - Kew Flower Pharmaceutical is well-positioned to leverage its strategic focus on innovation and quality to capture a larger share of the expanding market [11].

随着夏季高温天气提前到来，广东作为"火炉"地区，儿童消暑祛火需求显著上升。葵花药业针对广东市 场特点，深挖产品内涵，通过多样化用户沟通内容，成功将小葵花露打造为药店连接家庭的桥梁。这 种"淡季不淡"的销售奇迹，不仅激发了品牌的流量势能，更为广东连锁药店提供了突破流量困局的解决 方案。 在用户体验层面，小葵花露实现了多项创新突破。常温储存技术让产品在三年保质期内成分稳定，极大 提升了存放便利性；儿童专利设计的抽拉式运动瓶盖，既防撒漏又避免呛咳，充分考虑了儿童用药的安 全性与便利性；清香甘甜的口味则真正从儿童需求出发，提升了产品的接受度。这些细节设计不仅让小 葵花露成为家长信赖的"妈妈放心药"，更使其成为药店连接育儿家庭的"黄金入口"。 数据显示，自2018年起，小葵花露在零售市场连续七年稳居金银花露品类全国销冠，2024年市占率突破 50%，在药店渠道的市场占比更是高达68.3%，远超同类产品。这种强大的流量吸引力与市场盈利能 力，使其成为儿童清热祛火赛道中的佼佼者。中康科技零售市场研究中心韩佳佳在峰会上分析指出，儿 科中成药市场集中度高达89.2%，以金银花露为代表的头部品种精准契合常态化清热解毒场景需求，小 ...